Salmon synthetic calcitonin and alendronate effects on bone quality in ovariectomized rats;EFFETTI DI CALCITONINA SINTETICA DI SALMONE ED ALENDRONATO SULLA QUALITA DELL'OSSO IN RATTE OVARIECTOMIZZATE

Minerva Medica

Volumn 88, Issue 11, 1997, Pages 469-477

  Giardino, R ^a  

^a RIZZOLI ORTHOPAEDIC INSTITUTE   (Italy)

Author keywords

Calcitonin, therapeutic use; Diphosphonates therapeutic use; Disease model, animal; Osteoporosis; Ovariectomy; Rats

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERALIZATION; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HISTOLOGY; MORPHOMETRICS; NONHUMAN; OSTEOPOROSIS; OVARIECTOMY; RAT; SUBCUTANEOUS DRUG ADMINISTRATION;

ALENDRONATE; ANALYSIS OF VARIANCE; ANIMALS; BONE AND BONES; BONE DENSITY; CALCITONIN; CRYSTALLOGRAPHY; FEMALE; MODELS, BIOLOGICAL; OSTEOPOROSIS; OVARIECTOMY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0030702807     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Copp DH. Calcitonin: discovery, development and clinical application. Clin Invest Med 1994;17(3):268-77.
2. Kanis JA, Gertz BJ, Singer F. Ortolani S. Rationale for the use of alendronate in osteoporosis. Osteoporosis Int 1995;5:1-13.
3. Liberman UA, Weiss SR, Broil J, Minne HW, Quany H, Bell NH et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995:333(2): 1437-43.
4. Fleisch H. New bisphosphonates in osteoporosis. Osteoporosis Int 1993;(Suppl 2):S15-22.